Comments on: Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk

Comments on: Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk https://insideout.vn/novartis-twice-yearly-leqvio-demonstrated-clinically-meaningful-statistically-significant-ldl-c-lowering-as-a-monotherapy-in-patients-at-low-or-moderate-ascvd-risk/ Inside Out Wed, 28 Aug 2024 05:37:43 +0000 hourly 1 https://wordpress.org/?v=6.6.2